Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Japanese Healthy Men

NCT00772759 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00772759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00772759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Japanese Healthy Men
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
February 28, 2009
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy